Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership

Read More >

Teva Launches Generic Diovan® in the United States

Read More >

FDA Approves Teva’s GRANIX® (tbo-filgrastim) Injection for Self-Administration

Read More >

Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product (Lipegfilgrastim) in Breast Cancer Patients

Read More >

Teva Announces Data on Granulocyte Colony Stimulating Factor Compounds for the Prevention of Chemotherapy-Induced Neutropenia in Breast Cancer Patients

Read More >

Teva Provides Update on Status of Neutroval™ (G-CSF) Biologics License Application Submitted to the U.S. Food and Drug Administration

Read More >

Teva Announces FDA Accepts BLA for XM02

Read More >

Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia

Read More >

Teva Introduces Fexofenadine HCL and Pseudoephedrine HCL Extended-Release Tablets; An Alternative to Allegra-D® 12 Hour Tablets

Read More >

Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin® (Human Growth Hormone)

Read More >

Lonza and Teva Announce Receipt of Regulatory Approval

Read More >

Teva and Lonza Announce Strategic Partnership to Become a Leading Global Provider of Biosimilars

Read More >

Teva Receives EU Marketing Authorization for TevaGrastim®

Read More >

Teva's Developed G-CSF is the First Biosimilar to Receive a Positive Opinion from European Union Regulators

Read More >
Loading...